Welcome to EpilepsyU.com a social network dedicated to the epilepsy community

Share This Post

Epilepsy / Featured Slider / Global / Medicine / Neurology / News / Seizures

The gene that turns epilepsy treatment deadly

The gene that turns epilepsy treatment deadly

11718474 - human brain ecg health monitoring of the electrical signals that cause seizures in the human mind and charting the cognitive mental function of the intelligence of the anatomy of the body.

Drug-induced hypersensitivity reactions (DIHRs) are serious and life threatening. A common example is the use of the antiepileptic drug carbamazepine, but the mechanisms that trigger it are unclear. Current scientific consensus holds that people who have a specific variation of the ‘human leukocyte antigen B’ (HLA-B) gene, which provides the code for making a protein that plays a critical role in the immune system, are more at risk of DIHR. However, the mechanism linking this gene to DIHR is currently unknown. As this specific variation, called HLA-B*15:02, is fairly common in people of South-East Asian descent, this is a serious problem for clinicians in the region.

Researchers at Universiti Teknologi MARA Selangor in Malaysia used computer modelling to mimic and analyse how the protein encoded by HLA-B*15:02 interacts with a range of antiepileptic medications. The researchers used various software to mimic how drugs interact with a specific region of the HLA protein that is crucial for its normal functionality. Since the HLA complex acts like a sort of identity card in our cells, anything interacting with it other than our own immune cells can cause problems.

Carbamazepine and another eight out of 26 antiepileptic drugs (AEDs) that were tested were found to bind strongly to the HLA complex in the simulation model. The team believes this strong binding is behind DIHRs in patients who carry the variant gene.

1-thegenethatt

The image shows how researchers predict AEDs (the multicolour sticks) bind to the HLA complex (pale green and grey plus magenta-coloured peptide). Credit: Universiti Teknologi MARA

Testing for HLA-B*15:02, which can be done in as few as four hours, should be incorporated into clinical practice as soon as possible, recommends the study’s lead researcher Mohd Zaki Salleh.

Source: Medical Xpress

Share This Post

Leave a Reply

Your email address will not be published. Required fields are marked *

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <s> <strike> <strong>

Lost Password

Register